EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review

Moira Bradfield Strydom, Sohil Khan, Ramesh L Walpola, Robert S Ware, Evelin Tiralongo

Journal of Medical Microbiology · 2023

DOI: 10.1099/jmm.0.001705 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medical Microbiology, 2023. Verfasst von Moira Bradfield Strydom und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia. Hauptthemen laut MEDLINE: Candidiasis, Vulvovaginal, Microbiota. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrent vulvovaginal candidiasis (RVVC) is a microbial, immune and sexual health disorder impacting up to 10 % of the adult female population. Fluconazole is a well-established antifungal drug commonly utilized for acute and long-term RVVC treatment. This insight review provides an overview of known vaginal and gastrointestinal microbiota characteristics in RVVC, presents the potential impacts of fluconazole therapy on multi-microbiome relationships and discusses implications for future research and clinical practice. Next-generation sequencing (NGS) and molecular methods to accurately define vaginal microbiota trends in RVVC are not comprehensively available, limiting understanding of microbiota roles in RVVC. Inconsistencies and variances in Lactobacillus profiles in RVVC women suggest poorly understood disease implications on the bacterial and fungal microbiomes. Investigations of environmental conditions like vaginal pH, drug therapy’s impact, especially fluconazole maintenance therapy, and the elucidation of multi-microbiome relationships in RVVC are required to further investigate disease pathogenesis and responsible antimicrobial prescribing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Candidiasis, VulvovaginalMicrobiotaAdultFemaleHumansAntifungal AgentsFluconazoleCandida albicansRecurrence

Stichwörter der Autor:innen

RVVCcandidiasisfluconazolemicrobiomerecurrent thrush

Substanzen

Antifungal AgentsFluconazole

Autor:innen und Institutionen

  • School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia.
  • Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.
  • School of Health Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

Zitieren

APA

Bradfield Strydom, M., Khan, S., Walpola, R. L., Ware, R. S., & Tiralongo, E. (2023). Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001705

Vancouver

Bradfield Strydom M, Khan S, Walpola RL, Ware RS, Tiralongo E. Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review. Journal of Medical Microbiology. 2023. doi:10.1099/jmm.0.001705

BibTeX
@article{BradfieldStrydom2023,
  author = {Bradfield Strydom, Moira and Khan, Sohil and Walpola, Ramesh L and Ware, Robert S and Tiralongo, Evelin},
  title = {Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review},
  journal = {Journal of Medical Microbiology},
  year = {2023},
  doi = {10.1099/jmm.0.001705}
}
Kostenlos starten →